| Literature DB >> 23641421 |
Leonard Moise1, Annie De Groot, Anthony Marcello, Ryan Tassone, William Martin, Leslie Cousens.
Abstract
EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.Entities:
Keywords: autoimmune diseases; immuno- therapy; immunoinformatics; immunomodulation; vaccines
Mesh:
Substances:
Year: 2013 PMID: 23641421
Source DB: PubMed Journal: R I Med J (2013) ISSN: 0363-7913